DORAL, Fla., Dec. 5, 2012 /PRNewswire/ -- CorTronix™ Biomedical Advancement Technologies, Inc. ("CorTronix" or "the Company") (OTCQB and Pinksheets: CBAT) a BioMedical device developer and manufacturer of next generation Telemetric Medical Devices announced that it has engaged Maplehurst IR, a financial marketing and investor relations firm to assist the company in building and maintaining shareholder awareness. CorTronix is expecting to develop its next generation of Mobile Cardio and next generation Telemetric Medical Devices in rapid succession.

CorTronix CEO Mr. Yoel Palomino stated: "As the company prepares itself for rapid growth we have enlisted the help of the Maplehurst IR team to help position our story properly so that we may effectively deliver our message to the street."

Richard Hull, Managing Partner of Maplehurst said: "After seeing the technology firsthand and visiting the lab I am looking forward to working alongside Mr. Palomino and his team at CorTronix™. The Cor line-up has the potential to be a game changer in this space and I am excited be a part of this project."

About CorTronix™ Biomedical Advancement Technologies, Inc.

CorTronix™ Technologies, Inc. is a BioMedical Corporation with a core competency in Mobile Cardio Devices.   The Company is in development stages of creating a complete product line that will consist of multiple revolutionary mobile devices with the capacity to acquire and process patients data through a consolidated "Single Source" Network.

CorTronix™ integrates existing medical procedures with cutting edge wireless technology through the Company's proprietary Network (CorLink™) with the intent of creating the next generation Telemetric Medical Devices.  The Company is in the final stages of developing the infrastructure of this Global Health Network that will significantly increase the overall ability for Medical Professionals to properly diagnose and analyze Patients data remotely and in real time.

The Company is currently developing software that are designed to run on various mobile software platforms including but not limited to the Android™ Operating System.  CorTronix™ BioMedical's proprietary software will be able to be used on any existing tablet that a health care provider already may use, and will also be creating its CorTab™ which will have all necessary technology integrated into a single unit that will be available for sale or lease through the Company directly. "Tablet" – referring to mobile devices such as "iPad™", Galaxy Tab™", etc. that run on Mobile Operating Platforms through wireless technology and Protocols.

Safe Harbor Statement

Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. The company cautions that these forward-looking statements are further qualified by other factors. The company undertakes no obligation to publicly update or revise any statements in this release, whether as a result of new information, future events or otherwise.

CBAT Investor Relations 
Maplehurst 
Tel: 917.838.3991

SOURCE CorTronix Biomedical Advancement Technologies, Inc.